FDTD Simulation of Magnetic Field Distribution in Normal and Blood Cancer for Treatment

Non-invasive cancer treatment has the potential to eliminate infection and scar formation associated with surgery to minimize side effects. Light stimulation can use for treatment to increase efficiency, reduce treatment costs, eliminate infection, etc. Magnetic fields can improve blood circulation...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of physics. Conference series 2021-06, Vol.1951 (1), p.12061
Hauptverfasser: Zulfa, V Z, Farahdina, U, Firdhaus, M, Aziz, I, Nasori, N, Endarko, E, Darsono, D, Rubiyanto, A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Non-invasive cancer treatment has the potential to eliminate infection and scar formation associated with surgery to minimize side effects. Light stimulation can use for treatment to increase efficiency, reduce treatment costs, eliminate infection, etc. Magnetic fields can improve blood circulation in tissues and stimulate the body’s metabolism. The magnetic field can induce joule heating and expand the blood vessels of cancerous tumors. These blood vessels increase the possibility of excess oxygen to enter the tumor creating obstacles to the survival of oxygen-rich cancers. In this study, we investigate finite difference times domain (FTDT) simulation of magnetic field in normal and blood cancer. The low frequency with range 10-10 6 is used in this study. The maximum magnetic field for normal blood and CLL1 is 400 nm and 250 nm in 125 cm electrode size. While for 50 nm electrode size, the maximum magnetic field in normal blood and CLL 1 is 400 nm and 300 nm. But there The maximum magnetic field for normal blood and CLL1 is 400 nm and 250 nm in 125 cm electrode size. While for 50 nm electrode size, the maximum magnetic field in normal blood and CLL 1 is 400 nm and 300 nm. But there is no peak for blood cancer in final stage CLL2.
ISSN:1742-6588
1742-6596
DOI:10.1088/1742-6596/1951/1/012061